nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—MAPK3—breast cancer	0.28	0.587	CbGaD
Sulindac—PTGS1—breast cancer	0.0658	0.138	CbGaD
Sulindac—CYP1A1—breast cancer	0.0602	0.126	CbGaD
Sulindac—CYP1A1—Toremifene—breast cancer	0.0587	0.309	CbGbCtD
Sulindac—PTGS2—breast cancer	0.0376	0.0788	CbGaD
Sulindac—ALB—breast cancer	0.0335	0.0702	CbGaD
Sulindac—CYP1A2—Anastrozole—breast cancer	0.0287	0.151	CbGbCtD
Sulindac—CYP1A2—Toremifene—breast cancer	0.0262	0.138	CbGbCtD
Sulindac—CYP1A1—Tamoxifen—breast cancer	0.0214	0.113	CbGbCtD
Sulindac—ALB—Irinotecan—breast cancer	0.0123	0.0647	CbGbCtD
Sulindac—ALB—Fluorouracil—breast cancer	0.0118	0.0621	CbGbCtD
Sulindac—CYP1A2—Tamoxifen—breast cancer	0.00958	0.0504	CbGbCtD
Sulindac—SLC22A6—Methotrexate—breast cancer	0.00764	0.0402	CbGbCtD
Sulindac—CYP1A2—Fluorouracil—breast cancer	0.00706	0.0372	CbGbCtD
Sulindac—ALB—Methotrexate—breast cancer	0.00651	0.0343	CbGbCtD
Sulindac—AKR1B1—mammary gland—breast cancer	0.00266	0.0502	CbGeAlD
Sulindac—AKR1B1—nipple—breast cancer	0.0022	0.0415	CbGeAlD
Sulindac—PPARD—mammary gland—breast cancer	0.00209	0.0395	CbGeAlD
Sulindac—PTGDR2—female reproductive system—breast cancer	0.00207	0.0391	CbGeAlD
Sulindac—MAPK3—mammary gland—breast cancer	0.00193	0.0364	CbGeAlD
Sulindac—AKR1B1—embryo—breast cancer	0.00182	0.0342	CbGeAlD
Sulindac—MAPK3—nipple—breast cancer	0.0016	0.0301	CbGeAlD
Sulindac—AKR1B1—epithelium—breast cancer	0.00148	0.0279	CbGeAlD
Sulindac—AKR1B1—endometrium—breast cancer	0.00133	0.0251	CbGeAlD
Sulindac—MAPK3—embryo—breast cancer	0.00132	0.0248	CbGeAlD
Sulindac—AKR1B1—uterus—breast cancer	0.00122	0.0231	CbGeAlD
Sulindac—AKR1B1—pituitary gland—breast cancer	0.0012	0.0227	CbGeAlD
Sulindac—AKR1B1—adipose tissue—breast cancer	0.0012	0.0226	CbGeAlD
Sulindac—AKR1B1—female reproductive system—breast cancer	0.0011	0.0208	CbGeAlD
Sulindac—AKR1B1—adrenal gland—breast cancer	0.00107	0.0203	CbGeAlD
Sulindac—MAPK3—epithelium—breast cancer	0.00107	0.0203	CbGeAlD
Sulindac—AKR1B1—bone marrow—breast cancer	0.00104	0.0196	CbGeAlD
Sulindac—MAPK3—skin of body—breast cancer	0.00102	0.0193	CbGeAlD
Sulindac—AKR1B1—female gonad—breast cancer	0.001	0.0189	CbGeAlD
Sulindac—MAPK3—endometrium—breast cancer	0.000963	0.0182	CbGeAlD
Sulindac—PPARD—adipose tissue—breast cancer	0.000942	0.0178	CbGeAlD
Sulindac—AKR1B1—endocrine gland—breast cancer	0.000932	0.0176	CbGeAlD
Sulindac—ALB—mammary gland—breast cancer	0.00092	0.0173	CbGeAlD
Sulindac—MAPK3—uterus—breast cancer	0.000888	0.0167	CbGeAlD
Sulindac—MAPK3—pituitary gland—breast cancer	0.000872	0.0164	CbGeAlD
Sulindac—MAPK3—adipose tissue—breast cancer	0.000868	0.0164	CbGeAlD
Sulindac—PPARD—female reproductive system—breast cancer	0.000866	0.0163	CbGeAlD
Sulindac—PPARD—adrenal gland—breast cancer	0.000845	0.0159	CbGeAlD
Sulindac—MAPK3—female reproductive system—breast cancer	0.000798	0.015	CbGeAlD
Sulindac—PPARD—female gonad—breast cancer	0.000788	0.0149	CbGeAlD
Sulindac—MAPK3—adrenal gland—breast cancer	0.000779	0.0147	CbGeAlD
Sulindac—MAPK3—bone marrow—breast cancer	0.000753	0.0142	CbGeAlD
Sulindac—PPARD—endocrine gland—breast cancer	0.000733	0.0138	CbGeAlD
Sulindac—MAPK3—female gonad—breast cancer	0.000726	0.0137	CbGeAlD
Sulindac—MAPK3—endocrine gland—breast cancer	0.000675	0.0127	CbGeAlD
Sulindac—AKR1B1—lymph node—breast cancer	0.000644	0.0121	CbGeAlD
Sulindac—PPARD—lymph node—breast cancer	0.000506	0.00955	CbGeAlD
Sulindac—CYP1A2—nipple—breast cancer	0.0005	0.00943	CbGeAlD
Sulindac—CYP1A1—nipple—breast cancer	0.000494	0.00931	CbGeAlD
Sulindac—MAPK3—lymph node—breast cancer	0.000467	0.0088	CbGeAlD
Sulindac—PTGS1—nipple—breast cancer	0.000434	0.00818	CbGeAlD
Sulindac—ALB—adrenal gland—breast cancer	0.000371	0.007	CbGeAlD
Sulindac—PTGS2—embryo—breast cancer	0.000342	0.00645	CbGeAlD
Sulindac—CYP1A1—epithelium—breast cancer	0.000332	0.00627	CbGeAlD
Sulindac—CYP1A1—skin of body—breast cancer	0.000316	0.00596	CbGeAlD
Sulindac—PTGS1—epithelium—breast cancer	0.000292	0.0055	CbGeAlD
Sulindac—PTGS2—epithelium—breast cancer	0.000279	0.00526	CbGeAlD
Sulindac—PTGS1—skin of body—breast cancer	0.000278	0.00524	CbGeAlD
Sulindac—CYP1A1—uterus—breast cancer	0.000275	0.00518	CbGeAlD
Sulindac—CYP1A1—adipose tissue—breast cancer	0.000269	0.00506	CbGeAlD
Sulindac—PTGS2—skin of body—breast cancer	0.000265	0.005	CbGeAlD
Sulindac—PTGS1—endometrium—breast cancer	0.000262	0.00494	CbGeAlD
Sulindac—PTGS2—endometrium—breast cancer	0.00025	0.00472	CbGeAlD
Sulindac—CYP1A1—female reproductive system—breast cancer	0.000247	0.00465	CbGeAlD
Sulindac—PTGS1—uterus—breast cancer	0.000241	0.00455	CbGeAlD
Sulindac—PTGS1—pituitary gland—breast cancer	0.000237	0.00447	CbGeAlD
Sulindac—PTGS1—adipose tissue—breast cancer	0.000236	0.00445	CbGeAlD
Sulindac—PTGS2—uterus—breast cancer	0.000231	0.00435	CbGeAlD
Sulindac—PTGS2—pituitary gland—breast cancer	0.000226	0.00427	CbGeAlD
Sulindac—PTGS2—adipose tissue—breast cancer	0.000226	0.00425	CbGeAlD
Sulindac—CYP1A1—female gonad—breast cancer	0.000225	0.00424	CbGeAlD
Sulindac—ALB—lymph node—breast cancer	0.000223	0.0042	CbGeAlD
Sulindac—PTGS1—female reproductive system—breast cancer	0.000217	0.00409	CbGeAlD
Sulindac—CYP1A2—endocrine gland—breast cancer	0.000212	0.00399	CbGeAlD
Sulindac—PTGS1—adrenal gland—breast cancer	0.000212	0.00399	CbGeAlD
Sulindac—CYP1A1—endocrine gland—breast cancer	0.000209	0.00394	CbGeAlD
Sulindac—PTGS2—female reproductive system—breast cancer	0.000207	0.00391	CbGeAlD
Sulindac—PTGS2—adrenal gland—breast cancer	0.000202	0.00381	CbGeAlD
Sulindac—PTGS1—female gonad—breast cancer	0.000197	0.00372	CbGeAlD
Sulindac—PTGS2—bone marrow—breast cancer	0.000196	0.00369	CbGeAlD
Sulindac—PTGS2—female gonad—breast cancer	0.000189	0.00356	CbGeAlD
Sulindac—PTGS1—endocrine gland—breast cancer	0.000184	0.00346	CbGeAlD
Sulindac—PTGS2—endocrine gland—breast cancer	0.000175	0.00331	CbGeAlD
Sulindac—CYP1A1—lymph node—breast cancer	0.000144	0.00272	CbGeAlD
Sulindac—PTGS1—lymph node—breast cancer	0.000127	0.00239	CbGeAlD
Sulindac—PTGS2—lymph node—breast cancer	0.000121	0.00229	CbGeAlD
Sulindac—Jaundice—Doxorubicin—breast cancer	3.82e-05	0.000281	CcSEcCtD
Sulindac—Anorexia—Docetaxel—breast cancer	3.82e-05	0.000281	CcSEcCtD
Sulindac—Shock—Capecitabine—breast cancer	3.82e-05	0.000281	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—breast cancer	3.81e-05	0.00028	CcSEcCtD
Sulindac—Hepatitis—Epirubicin—breast cancer	3.81e-05	0.00028	CcSEcCtD
Sulindac—Diarrhoea—Fluorouracil—breast cancer	3.8e-05	0.000279	CcSEcCtD
Sulindac—Thrombocytopenia—Capecitabine—breast cancer	3.8e-05	0.000279	CcSEcCtD
Sulindac—Tinnitus—Methotrexate—breast cancer	3.79e-05	0.000279	CcSEcCtD
Sulindac—Tachycardia—Capecitabine—breast cancer	3.79e-05	0.000278	CcSEcCtD
Sulindac—Sweating—Doxorubicin—breast cancer	3.76e-05	0.000276	CcSEcCtD
Sulindac—Urticaria—Paclitaxel—breast cancer	3.76e-05	0.000276	CcSEcCtD
Sulindac—Hyperhidrosis—Capecitabine—breast cancer	3.75e-05	0.000276	CcSEcCtD
Sulindac—Hypotension—Docetaxel—breast cancer	3.75e-05	0.000275	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—breast cancer	3.74e-05	0.000275	CcSEcCtD
Sulindac—Body temperature increased—Paclitaxel—breast cancer	3.74e-05	0.000275	CcSEcCtD
Sulindac—Epistaxis—Doxorubicin—breast cancer	3.7e-05	0.000272	CcSEcCtD
Sulindac—Anorexia—Capecitabine—breast cancer	3.7e-05	0.000272	CcSEcCtD
Sulindac—Vomiting—Mitoxantrone—breast cancer	3.69e-05	0.000271	CcSEcCtD
Sulindac—Vomiting—Irinotecan—breast cancer	3.69e-05	0.000271	CcSEcCtD
Sulindac—Dizziness—Fluorouracil—breast cancer	3.67e-05	0.00027	CcSEcCtD
Sulindac—Visual impairment—Epirubicin—breast cancer	3.67e-05	0.00027	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—breast cancer	3.66e-05	0.000269	CcSEcCtD
Sulindac—Rash—Mitoxantrone—breast cancer	3.66e-05	0.000269	CcSEcCtD
Sulindac—Rash—Irinotecan—breast cancer	3.66e-05	0.000269	CcSEcCtD
Sulindac—Dermatitis—Mitoxantrone—breast cancer	3.65e-05	0.000268	CcSEcCtD
Sulindac—Dermatitis—Irinotecan—breast cancer	3.65e-05	0.000268	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Docetaxel—breast cancer	3.65e-05	0.000268	CcSEcCtD
Sulindac—Chills—Methotrexate—breast cancer	3.65e-05	0.000268	CcSEcCtD
Sulindac—Headache—Mitoxantrone—breast cancer	3.63e-05	0.000267	CcSEcCtD
Sulindac—Headache—Irinotecan—breast cancer	3.63e-05	0.000267	CcSEcCtD
Sulindac—Hypotension—Capecitabine—breast cancer	3.63e-05	0.000267	CcSEcCtD
Sulindac—Insomnia—Docetaxel—breast cancer	3.63e-05	0.000266	CcSEcCtD
Sulindac—Paraesthesia—Docetaxel—breast cancer	3.6e-05	0.000265	CcSEcCtD
Sulindac—Erythema multiforme—Epirubicin—breast cancer	3.6e-05	0.000264	CcSEcCtD
Sulindac—Alopecia—Methotrexate—breast cancer	3.59e-05	0.000264	CcSEcCtD
Sulindac—Vomiting—Gemcitabine—breast cancer	3.59e-05	0.000264	CcSEcCtD
Sulindac—Dyspnoea—Docetaxel—breast cancer	3.57e-05	0.000263	CcSEcCtD
Sulindac—Somnolence—Docetaxel—breast cancer	3.56e-05	0.000262	CcSEcCtD
Sulindac—Rash—Gemcitabine—breast cancer	3.56e-05	0.000262	CcSEcCtD
Sulindac—Dermatitis—Gemcitabine—breast cancer	3.56e-05	0.000262	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—breast cancer	3.55e-05	0.000261	CcSEcCtD
Sulindac—Headache—Gemcitabine—breast cancer	3.54e-05	0.00026	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Capecitabine—breast cancer	3.54e-05	0.00026	CcSEcCtD
Sulindac—Flushing—Epirubicin—breast cancer	3.53e-05	0.00026	CcSEcCtD
Sulindac—Vomiting—Fluorouracil—breast cancer	3.53e-05	0.00026	CcSEcCtD
Sulindac—Dyspepsia—Docetaxel—breast cancer	3.53e-05	0.000259	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—breast cancer	3.52e-05	0.000259	CcSEcCtD
Sulindac—Insomnia—Capecitabine—breast cancer	3.51e-05	0.000258	CcSEcCtD
Sulindac—Rash—Fluorouracil—breast cancer	3.5e-05	0.000257	CcSEcCtD
Sulindac—Dermatitis—Fluorouracil—breast cancer	3.5e-05	0.000257	CcSEcCtD
Sulindac—Paraesthesia—Capecitabine—breast cancer	3.48e-05	0.000256	CcSEcCtD
Sulindac—Decreased appetite—Docetaxel—breast cancer	3.48e-05	0.000256	CcSEcCtD
Sulindac—Hypersensitivity—Paclitaxel—breast cancer	3.48e-05	0.000256	CcSEcCtD
Sulindac—Headache—Fluorouracil—breast cancer	3.48e-05	0.000256	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—breast cancer	3.47e-05	0.000255	CcSEcCtD
Sulindac—Dyspnoea—Capecitabine—breast cancer	3.46e-05	0.000254	CcSEcCtD
Sulindac—Fatigue—Docetaxel—breast cancer	3.46e-05	0.000254	CcSEcCtD
Sulindac—Nausea—Irinotecan—breast cancer	3.44e-05	0.000253	CcSEcCtD
Sulindac—Nausea—Mitoxantrone—breast cancer	3.44e-05	0.000253	CcSEcCtD
Sulindac—Constipation—Docetaxel—breast cancer	3.43e-05	0.000252	CcSEcCtD
Sulindac—Dyspepsia—Capecitabine—breast cancer	3.42e-05	0.000251	CcSEcCtD
Sulindac—Chills—Epirubicin—breast cancer	3.41e-05	0.000251	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—breast cancer	3.4e-05	0.00025	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—breast cancer	3.39e-05	0.000249	CcSEcCtD
Sulindac—Asthenia—Paclitaxel—breast cancer	3.39e-05	0.000249	CcSEcCtD
Sulindac—Decreased appetite—Capecitabine—breast cancer	3.37e-05	0.000248	CcSEcCtD
Sulindac—Alopecia—Epirubicin—breast cancer	3.36e-05	0.000247	CcSEcCtD
Sulindac—Nausea—Gemcitabine—breast cancer	3.36e-05	0.000247	CcSEcCtD
Sulindac—Fatigue—Capecitabine—breast cancer	3.35e-05	0.000246	CcSEcCtD
Sulindac—Pruritus—Paclitaxel—breast cancer	3.35e-05	0.000246	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—breast cancer	3.34e-05	0.000245	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—breast cancer	3.33e-05	0.000245	CcSEcCtD
Sulindac—Constipation—Capecitabine—breast cancer	3.32e-05	0.000244	CcSEcCtD
Sulindac—Feeling abnormal—Docetaxel—breast cancer	3.3e-05	0.000243	CcSEcCtD
Sulindac—Nausea—Fluorouracil—breast cancer	3.3e-05	0.000242	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—breast cancer	3.28e-05	0.000241	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—breast cancer	3.28e-05	0.000241	CcSEcCtD
Sulindac—Gastrointestinal pain—Docetaxel—breast cancer	3.28e-05	0.000241	CcSEcCtD
Sulindac—Anaemia—Methotrexate—breast cancer	3.27e-05	0.00024	CcSEcCtD
Sulindac—Flushing—Doxorubicin—breast cancer	3.27e-05	0.00024	CcSEcCtD
Sulindac—Flatulence—Epirubicin—breast cancer	3.26e-05	0.00024	CcSEcCtD
Sulindac—Tension—Epirubicin—breast cancer	3.25e-05	0.000239	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—breast cancer	3.24e-05	0.000238	CcSEcCtD
Sulindac—Diarrhoea—Paclitaxel—breast cancer	3.24e-05	0.000238	CcSEcCtD
Sulindac—Nervousness—Epirubicin—breast cancer	3.22e-05	0.000237	CcSEcCtD
Sulindac—Feeling abnormal—Capecitabine—breast cancer	3.2e-05	0.000235	CcSEcCtD
Sulindac—Malaise—Methotrexate—breast cancer	3.19e-05	0.000235	CcSEcCtD
Sulindac—Vertigo—Methotrexate—breast cancer	3.18e-05	0.000234	CcSEcCtD
Sulindac—Gastrointestinal pain—Capecitabine—breast cancer	3.17e-05	0.000233	CcSEcCtD
Sulindac—Body temperature increased—Docetaxel—breast cancer	3.17e-05	0.000233	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—breast cancer	3.17e-05	0.000233	CcSEcCtD
Sulindac—Chills—Doxorubicin—breast cancer	3.16e-05	0.000232	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—breast cancer	3.15e-05	0.000231	CcSEcCtD
Sulindac—Dizziness—Paclitaxel—breast cancer	3.13e-05	0.00023	CcSEcCtD
Sulindac—Vision blurred—Epirubicin—breast cancer	3.12e-05	0.000229	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—breast cancer	3.11e-05	0.000229	CcSEcCtD
Sulindac—Urticaria—Capecitabine—breast cancer	3.08e-05	0.000227	CcSEcCtD
Sulindac—Ill-defined disorder—Epirubicin—breast cancer	3.07e-05	0.000226	CcSEcCtD
Sulindac—Body temperature increased—Capecitabine—breast cancer	3.07e-05	0.000226	CcSEcCtD
Sulindac—Convulsion—Methotrexate—breast cancer	3.07e-05	0.000225	CcSEcCtD
Sulindac—Anaemia—Epirubicin—breast cancer	3.06e-05	0.000225	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—breast cancer	3.02e-05	0.000222	CcSEcCtD
Sulindac—Chest pain—Methotrexate—breast cancer	3.01e-05	0.000222	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—breast cancer	3.01e-05	0.000222	CcSEcCtD
Sulindac—Myalgia—Methotrexate—breast cancer	3.01e-05	0.000222	CcSEcCtD
Sulindac—Tension—Doxorubicin—breast cancer	3.01e-05	0.000221	CcSEcCtD
Sulindac—Vomiting—Paclitaxel—breast cancer	3.01e-05	0.000221	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—breast cancer	3e-05	0.000221	CcSEcCtD
Sulindac—Malaise—Epirubicin—breast cancer	2.99e-05	0.00022	CcSEcCtD
Sulindac—Rash—Paclitaxel—breast cancer	2.98e-05	0.000219	CcSEcCtD
Sulindac—Dermatitis—Paclitaxel—breast cancer	2.98e-05	0.000219	CcSEcCtD
Sulindac—Discomfort—Methotrexate—breast cancer	2.98e-05	0.000219	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—breast cancer	2.98e-05	0.000219	CcSEcCtD
Sulindac—Vertigo—Epirubicin—breast cancer	2.98e-05	0.000219	CcSEcCtD
Sulindac—Syncope—Epirubicin—breast cancer	2.97e-05	0.000218	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—breast cancer	2.97e-05	0.000218	CcSEcCtD
Sulindac—Headache—Paclitaxel—breast cancer	2.96e-05	0.000218	CcSEcCtD
Sulindac—Hypersensitivity—Docetaxel—breast cancer	2.95e-05	0.000217	CcSEcCtD
Sulindac—Palpitations—Epirubicin—breast cancer	2.93e-05	0.000215	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—breast cancer	2.91e-05	0.000214	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—breast cancer	2.89e-05	0.000212	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—breast cancer	2.89e-05	0.000212	CcSEcCtD
Sulindac—Asthenia—Docetaxel—breast cancer	2.88e-05	0.000211	CcSEcCtD
Sulindac—Convulsion—Epirubicin—breast cancer	2.87e-05	0.000211	CcSEcCtD
Sulindac—Hypertension—Epirubicin—breast cancer	2.86e-05	0.00021	CcSEcCtD
Sulindac—Hypersensitivity—Capecitabine—breast cancer	2.86e-05	0.00021	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—breast cancer	2.84e-05	0.000209	CcSEcCtD
Sulindac—Pruritus—Docetaxel—breast cancer	2.84e-05	0.000208	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—breast cancer	2.83e-05	0.000208	CcSEcCtD
Sulindac—Thrombocytopenia—Methotrexate—breast cancer	2.83e-05	0.000208	CcSEcCtD
Sulindac—Chest pain—Epirubicin—breast cancer	2.82e-05	0.000207	CcSEcCtD
Sulindac—Myalgia—Epirubicin—breast cancer	2.82e-05	0.000207	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—breast cancer	2.82e-05	0.000207	CcSEcCtD
Sulindac—Nausea—Paclitaxel—breast cancer	2.81e-05	0.000206	CcSEcCtD
Sulindac—Hyperhidrosis—Methotrexate—breast cancer	2.79e-05	0.000205	CcSEcCtD
Sulindac—Discomfort—Epirubicin—breast cancer	2.79e-05	0.000205	CcSEcCtD
Sulindac—Asthenia—Capecitabine—breast cancer	2.78e-05	0.000205	CcSEcCtD
Sulindac—Malaise—Doxorubicin—breast cancer	2.76e-05	0.000203	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—breast cancer	2.75e-05	0.000202	CcSEcCtD
Sulindac—Anorexia—Methotrexate—breast cancer	2.75e-05	0.000202	CcSEcCtD
Sulindac—Syncope—Doxorubicin—breast cancer	2.75e-05	0.000202	CcSEcCtD
Sulindac—Pruritus—Capecitabine—breast cancer	2.75e-05	0.000202	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—breast cancer	2.74e-05	0.000202	CcSEcCtD
Sulindac—Diarrhoea—Docetaxel—breast cancer	2.74e-05	0.000202	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—breast cancer	2.71e-05	0.000199	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—breast cancer	2.7e-05	0.000199	CcSEcCtD
Sulindac—Oedema—Epirubicin—breast cancer	2.7e-05	0.000199	CcSEcCtD
Sulindac—Hypotension—Methotrexate—breast cancer	2.7e-05	0.000198	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—breast cancer	2.69e-05	0.000198	CcSEcCtD
Sulindac—Shock—Epirubicin—breast cancer	2.66e-05	0.000196	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—breast cancer	2.66e-05	0.000195	CcSEcCtD
Sulindac—Diarrhoea—Capecitabine—breast cancer	2.66e-05	0.000195	CcSEcCtD
Sulindac—Dizziness—Docetaxel—breast cancer	2.65e-05	0.000195	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—breast cancer	2.65e-05	0.000195	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—breast cancer	2.65e-05	0.000195	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—breast cancer	2.64e-05	0.000194	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methotrexate—breast cancer	2.63e-05	0.000193	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—breast cancer	2.61e-05	0.000192	CcSEcCtD
Sulindac—Insomnia—Methotrexate—breast cancer	2.61e-05	0.000192	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—breast cancer	2.61e-05	0.000192	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—breast cancer	2.61e-05	0.000192	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—breast cancer	2.61e-05	0.000192	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—breast cancer	2.59e-05	0.000191	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—breast cancer	2.58e-05	0.00019	CcSEcCtD
Sulindac—Anorexia—Epirubicin—breast cancer	2.58e-05	0.000189	CcSEcCtD
Sulindac—Dyspnoea—Methotrexate—breast cancer	2.58e-05	0.000189	CcSEcCtD
Sulindac—Somnolence—Methotrexate—breast cancer	2.57e-05	0.000189	CcSEcCtD
Sulindac—Dizziness—Capecitabine—breast cancer	2.57e-05	0.000189	CcSEcCtD
Sulindac—Vomiting—Docetaxel—breast cancer	2.55e-05	0.000187	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—breast cancer	2.54e-05	0.000187	CcSEcCtD
Sulindac—Rash—Docetaxel—breast cancer	2.53e-05	0.000186	CcSEcCtD
Sulindac—Hypotension—Epirubicin—breast cancer	2.53e-05	0.000186	CcSEcCtD
Sulindac—Dermatitis—Docetaxel—breast cancer	2.52e-05	0.000186	CcSEcCtD
Sulindac—Decreased appetite—Methotrexate—breast cancer	2.51e-05	0.000185	CcSEcCtD
Sulindac—Headache—Docetaxel—breast cancer	2.51e-05	0.000185	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—breast cancer	2.5e-05	0.000184	CcSEcCtD
Sulindac—Oedema—Doxorubicin—breast cancer	2.5e-05	0.000184	CcSEcCtD
Sulindac—Fatigue—Methotrexate—breast cancer	2.49e-05	0.000183	CcSEcCtD
Sulindac—Vomiting—Capecitabine—breast cancer	2.47e-05	0.000181	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—breast cancer	2.46e-05	0.000181	CcSEcCtD
Sulindac—Shock—Doxorubicin—breast cancer	2.46e-05	0.000181	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—breast cancer	2.45e-05	0.00018	CcSEcCtD
Sulindac—Rash—Capecitabine—breast cancer	2.45e-05	0.00018	CcSEcCtD
Sulindac—Insomnia—Epirubicin—breast cancer	2.45e-05	0.00018	CcSEcCtD
Sulindac—Dermatitis—Capecitabine—breast cancer	2.44e-05	0.00018	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—breast cancer	2.44e-05	0.000179	CcSEcCtD
Sulindac—Headache—Capecitabine—breast cancer	2.43e-05	0.000179	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—breast cancer	2.43e-05	0.000178	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—breast cancer	2.42e-05	0.000178	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—breast cancer	2.41e-05	0.000177	CcSEcCtD
Sulindac—Somnolence—Epirubicin—breast cancer	2.4e-05	0.000177	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—breast cancer	2.38e-05	0.000175	CcSEcCtD
Sulindac—Nausea—Docetaxel—breast cancer	2.38e-05	0.000175	CcSEcCtD
Sulindac—Feeling abnormal—Methotrexate—breast cancer	2.38e-05	0.000175	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—breast cancer	2.38e-05	0.000175	CcSEcCtD
Sulindac—Gastrointestinal pain—Methotrexate—breast cancer	2.36e-05	0.000174	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—breast cancer	2.35e-05	0.000173	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—breast cancer	2.34e-05	0.000172	CcSEcCtD
Sulindac—Fatigue—Epirubicin—breast cancer	2.33e-05	0.000171	CcSEcCtD
Sulindac—Constipation—Epirubicin—breast cancer	2.31e-05	0.00017	CcSEcCtD
Sulindac—Nausea—Capecitabine—breast cancer	2.31e-05	0.000169	CcSEcCtD
Sulindac—Urticaria—Methotrexate—breast cancer	2.3e-05	0.000169	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—breast cancer	2.28e-05	0.000168	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.28e-05	0.000168	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—breast cancer	2.26e-05	0.000166	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—breast cancer	2.25e-05	0.000165	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—breast cancer	2.23e-05	0.000164	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—breast cancer	2.23e-05	0.000164	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—breast cancer	2.22e-05	0.000163	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—breast cancer	2.21e-05	0.000163	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—breast cancer	2.2e-05	0.000162	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—breast cancer	2.17e-05	0.00016	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—breast cancer	2.16e-05	0.000159	CcSEcCtD
Sulindac—Urticaria—Epirubicin—breast cancer	2.15e-05	0.000158	CcSEcCtD
Sulindac—Constipation—Doxorubicin—breast cancer	2.14e-05	0.000157	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—breast cancer	2.14e-05	0.000157	CcSEcCtD
Sulindac—Hypersensitivity—Methotrexate—breast cancer	2.13e-05	0.000156	CcSEcCtD
Sulindac—Asthenia—Methotrexate—breast cancer	2.07e-05	0.000152	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—breast cancer	2.06e-05	0.000152	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—breast cancer	2.05e-05	0.00015	CcSEcCtD
Sulindac—Pruritus—Methotrexate—breast cancer	2.04e-05	0.00015	CcSEcCtD
Sulindac—Hypersensitivity—Epirubicin—breast cancer	1.99e-05	0.000146	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—breast cancer	1.99e-05	0.000146	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—breast cancer	1.98e-05	0.000145	CcSEcCtD
Sulindac—Diarrhoea—Methotrexate—breast cancer	1.98e-05	0.000145	CcSEcCtD
Sulindac—Asthenia—Epirubicin—breast cancer	1.94e-05	0.000143	CcSEcCtD
Sulindac—Pruritus—Epirubicin—breast cancer	1.91e-05	0.000141	CcSEcCtD
Sulindac—Dizziness—Methotrexate—breast cancer	1.91e-05	0.00014	CcSEcCtD
Sulindac—Diarrhoea—Epirubicin—breast cancer	1.85e-05	0.000136	CcSEcCtD
Sulindac—Hypersensitivity—Doxorubicin—breast cancer	1.84e-05	0.000135	CcSEcCtD
Sulindac—Vomiting—Methotrexate—breast cancer	1.84e-05	0.000135	CcSEcCtD
Sulindac—Rash—Methotrexate—breast cancer	1.82e-05	0.000134	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—breast cancer	1.82e-05	0.000134	CcSEcCtD
Sulindac—Headache—Methotrexate—breast cancer	1.81e-05	0.000133	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—breast cancer	1.79e-05	0.000132	CcSEcCtD
Sulindac—Dizziness—Epirubicin—breast cancer	1.79e-05	0.000131	CcSEcCtD
Sulindac—Pruritus—Doxorubicin—breast cancer	1.77e-05	0.00013	CcSEcCtD
Sulindac—Vomiting—Epirubicin—breast cancer	1.72e-05	0.000126	CcSEcCtD
Sulindac—Nausea—Methotrexate—breast cancer	1.72e-05	0.000126	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—breast cancer	1.71e-05	0.000126	CcSEcCtD
Sulindac—Rash—Epirubicin—breast cancer	1.7e-05	0.000125	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—breast cancer	1.7e-05	0.000125	CcSEcCtD
Sulindac—Headache—Epirubicin—breast cancer	1.69e-05	0.000124	CcSEcCtD
Sulindac—Dizziness—Doxorubicin—breast cancer	1.65e-05	0.000122	CcSEcCtD
Sulindac—Nausea—Epirubicin—breast cancer	1.61e-05	0.000118	CcSEcCtD
Sulindac—Vomiting—Doxorubicin—breast cancer	1.59e-05	0.000117	CcSEcCtD
Sulindac—Rash—Doxorubicin—breast cancer	1.58e-05	0.000116	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—breast cancer	1.58e-05	0.000116	CcSEcCtD
Sulindac—Headache—Doxorubicin—breast cancer	1.57e-05	0.000115	CcSEcCtD
Sulindac—Nausea—Doxorubicin—breast cancer	1.49e-05	0.000109	CcSEcCtD
Sulindac—PTGS1—Metabolism—CAV1—breast cancer	1.82e-06	1.26e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.81e-06	1.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGFR1—breast cancer	1.81e-06	1.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CTNNB1—breast cancer	1.79e-06	1.25e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP1B1—breast cancer	1.79e-06	1.25e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TYMS—breast cancer	1.79e-06	1.24e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—RAF1—breast cancer	1.78e-06	1.24e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HIF1A—breast cancer	1.78e-06	1.24e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MED12—breast cancer	1.78e-06	1.24e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—DPYD—breast cancer	1.78e-06	1.24e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PLA2G4A—breast cancer	1.77e-06	1.23e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NCOR1—breast cancer	1.77e-06	1.23e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTM1—breast cancer	1.77e-06	1.23e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HSP90AA1—breast cancer	1.75e-06	1.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—SRC—breast cancer	1.75e-06	1.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN1A—breast cancer	1.75e-06	1.22e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALDOA—breast cancer	1.75e-06	1.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTEN—breast cancer	1.74e-06	1.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BRAF—breast cancer	1.73e-06	1.21e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.73e-06	1.21e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.73e-06	1.21e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CAV1—breast cancer	1.72e-06	1.2e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—COMT—breast cancer	1.72e-06	1.19e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTP1—breast cancer	1.71e-06	1.19e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—NCOA1—breast cancer	1.71e-06	1.19e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOA3—breast cancer	1.7e-06	1.18e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GPX1—breast cancer	1.69e-06	1.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STAT3—breast cancer	1.69e-06	1.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF1—breast cancer	1.69e-06	1.18e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT2—breast cancer	1.69e-06	1.18e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC2A2—breast cancer	1.69e-06	1.17e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HMOX1—breast cancer	1.68e-06	1.17e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—STK11—breast cancer	1.68e-06	1.17e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP19A1—breast cancer	1.68e-06	1.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—EGFR—breast cancer	1.68e-06	1.17e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ITPR1—breast cancer	1.68e-06	1.17e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP1A1—breast cancer	1.68e-06	1.17e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	1.67e-06	1.16e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ERCC2—breast cancer	1.66e-06	1.16e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CG—breast cancer	1.65e-06	1.15e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CPT1A—breast cancer	1.65e-06	1.15e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MTR—breast cancer	1.65e-06	1.15e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCG2—breast cancer	1.65e-06	1.15e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—breast cancer	1.65e-06	1.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CD—breast cancer	1.62e-06	1.13e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HPGDS—breast cancer	1.62e-06	1.13e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS2—breast cancer	1.62e-06	1.13e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—SRC—breast cancer	1.62e-06	1.13e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ABCB1—breast cancer	1.62e-06	1.13e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HBA1—breast cancer	1.61e-06	1.12e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SRC—breast cancer	1.61e-06	1.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SERPINE1—breast cancer	1.6e-06	1.12e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOTCH1—breast cancer	1.6e-06	1.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—breast cancer	1.59e-06	1.11e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TYMS—breast cancer	1.59e-06	1.1e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.58e-06	1.1e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTT1—breast cancer	1.57e-06	1.09e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ACHE—breast cancer	1.57e-06	1.09e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PLA2G4A—breast cancer	1.57e-06	1.09e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTM1—breast cancer	1.57e-06	1.09e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NCOR1—breast cancer	1.57e-06	1.09e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APC—breast cancer	1.57e-06	1.09e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KIT—breast cancer	1.57e-06	1.09e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—breast cancer	1.57e-06	1.09e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—COMT—breast cancer	1.56e-06	1.09e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MTHFR—breast cancer	1.56e-06	1.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—breast cancer	1.56e-06	1.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—STAT3—breast cancer	1.56e-06	1.09e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTP1—breast cancer	1.56e-06	1.08e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGF—breast cancer	1.55e-06	1.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EGFR—breast cancer	1.54e-06	1.07e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—HMOX1—breast cancer	1.53e-06	1.07e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NOS3—breast cancer	1.53e-06	1.07e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ITPR1—breast cancer	1.53e-06	1.07e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GPX1—breast cancer	1.5e-06	1.05e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP17A1—breast cancer	1.49e-06	1.03e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MAPK3—breast cancer	1.48e-06	1.03e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ERCC2—breast cancer	1.47e-06	1.03e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—BRAF—breast cancer	1.47e-06	1.03e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ABCB1—breast cancer	1.47e-06	1.03e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS1—breast cancer	1.47e-06	1.02e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ENO1—breast cancer	1.47e-06	1.02e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	1.47e-06	1.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CA—breast cancer	1.46e-06	1.02e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CD—breast cancer	1.45e-06	1.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MDM2—breast cancer	1.45e-06	1.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—breast cancer	1.45e-06	1.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—breast cancer	1.45e-06	1.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RAF1—breast cancer	1.45e-06	1.01e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	1.45e-06	1.01e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—TYMS—breast cancer	1.45e-06	1.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFB1—breast cancer	1.45e-06	1.01e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP2D6—breast cancer	1.44e-06	1e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RELA—breast cancer	1.44e-06	1e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CAV1—breast cancer	1.44e-06	1e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TGFB1—breast cancer	1.44e-06	1e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ALB—breast cancer	1.43e-06	9.99e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT2—breast cancer	1.43e-06	9.98e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ERBB2—breast cancer	1.43e-06	9.98e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTM1—breast cancer	1.43e-06	9.96e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PLA2G4A—breast cancer	1.43e-06	9.96e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—NCOR1—breast cancer	1.43e-06	9.96e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—EGFR—breast cancer	1.42e-06	9.87e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOA2—breast cancer	1.42e-06	9.86e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CB—breast cancer	1.41e-06	9.85e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MTOR—breast cancer	1.41e-06	9.85e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MTHFR—breast cancer	1.39e-06	9.65e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CD—breast cancer	1.38e-06	9.59e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.38e-06	9.58e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—FASN—breast cancer	1.37e-06	9.56e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NOS3—breast cancer	1.37e-06	9.56e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—GPX1—breast cancer	1.37e-06	9.53e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—BCHE—breast cancer	1.37e-06	9.52e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—SERPINE1—breast cancer	1.36e-06	9.49e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL8—breast cancer	1.36e-06	9.46e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP1A1—breast cancer	1.36e-06	9.44e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC5A5—breast cancer	1.35e-06	9.41e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—breast cancer	1.35e-06	9.4e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—ERCC2—breast cancer	1.34e-06	9.36e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—breast cancer	1.34e-06	9.33e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CA—breast cancer	1.33e-06	9.28e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—breast cancer	1.33e-06	9.27e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1B—breast cancer	1.33e-06	9.24e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CG—breast cancer	1.31e-06	9.14e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC2A1—breast cancer	1.31e-06	9.09e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NQO1—breast cancer	1.31e-06	9.09e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS3—breast cancer	1.3e-06	9.06e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP3—breast cancer	1.3e-06	9.06e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—breast cancer	1.3e-06	9.04e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—breast cancer	1.29e-06	9e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CAV1—breast cancer	1.28e-06	8.9e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.28e-06	8.9e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP3A4—breast cancer	1.27e-06	8.86e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CB—breast cancer	1.27e-06	8.82e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.27e-06	8.82e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCND1—breast cancer	1.27e-06	8.81e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—MTHFR—breast cancer	1.26e-06	8.8e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JUN—breast cancer	1.26e-06	8.8e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—breast cancer	1.26e-06	8.74e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CTNNB1—breast cancer	1.25e-06	8.73e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP1B1—breast cancer	1.25e-06	8.71e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MDM2—breast cancer	1.23e-06	8.59e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—breast cancer	1.23e-06	8.59e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CA—breast cancer	1.23e-06	8.57e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—RAF1—breast cancer	1.23e-06	8.56e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—breast cancer	1.23e-06	8.56e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HSP90AA1—breast cancer	1.23e-06	8.54e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1A—breast cancer	1.22e-06	8.53e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CA—breast cancer	1.22e-06	8.52e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTEN—breast cancer	1.22e-06	8.51e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.22e-06	8.51e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—ERBB2—breast cancer	1.22e-06	8.47e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CB—breast cancer	1.2e-06	8.36e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTOR—breast cancer	1.2e-06	8.36e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD4—breast cancer	1.2e-06	8.35e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAPK8—breast cancer	1.2e-06	8.32e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOA1—breast cancer	1.19e-06	8.31e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—breast cancer	1.19e-06	8.3e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—breast cancer	1.18e-06	8.24e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—breast cancer	1.18e-06	8.22e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—STK11—breast cancer	1.18e-06	8.19e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP19A1—breast cancer	1.18e-06	8.19e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—CAV1—breast cancer	1.17e-06	8.12e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CG—breast cancer	1.16e-06	8.11e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CD—breast cancer	1.15e-06	8.03e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ALB—breast cancer	1.14e-06	7.93e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—breast cancer	1.14e-06	7.93e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SRC—breast cancer	1.13e-06	7.89e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—breast cancer	1.13e-06	7.88e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1B—breast cancer	1.13e-06	7.85e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.11e-06	7.75e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.1e-06	7.69e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—breast cancer	1.1e-06	7.68e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTEN—breast cancer	1.09e-06	7.62e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—COMT—breast cancer	1.09e-06	7.61e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT3—breast cancer	1.09e-06	7.61e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—breast cancer	1.09e-06	7.59e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NOS3—breast cancer	1.09e-06	7.59e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—breast cancer	1.09e-06	7.58e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTP1—breast cancer	1.09e-06	7.58e-06	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—breast cancer	1.08e-06	7.54e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HMOX1—breast cancer	1.07e-06	7.47e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ITPR1—breast cancer	1.07e-06	7.46e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CTNNB1—breast cancer	1.06e-06	7.41e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CG—breast cancer	1.06e-06	7.39e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1A—breast cancer	1.04e-06	7.24e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTEN—breast cancer	1.04e-06	7.22e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCB1—breast cancer	1.03e-06	7.17e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CD—breast cancer	1.02e-06	7.13e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—breast cancer	1.02e-06	7.07e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFB1—breast cancer	1.01e-06	7.05e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TYMS—breast cancer	1.01e-06	7.05e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ALB—breast cancer	1.01e-06	7.04e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CB—breast cancer	1.01e-06	7e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—breast cancer	1.01e-06	7e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOR1—breast cancer	1e-06	6.96e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PLA2G4A—breast cancer	1e-06	6.96e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTM1—breast cancer	1e-06	6.96e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—breast cancer	9.99e-07	6.96e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGFR—breast cancer	9.93e-07	6.92e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NOS3—breast cancer	9.67e-07	6.73e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—SRC—breast cancer	9.62e-07	6.7e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GPX1—breast cancer	9.58e-07	6.67e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP1A1—breast cancer	9.48e-07	6.6e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ERCC2—breast cancer	9.4e-07	6.55e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—breast cancer	9.38e-07	6.53e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CD—breast cancer	9.34e-07	6.5e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—STAT3—breast cancer	9.28e-07	6.46e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CB—breast cancer	8.93e-07	6.21e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAPK3—breast cancer	8.87e-07	6.17e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—breast cancer	8.84e-07	6.16e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MTHFR—breast cancer	8.84e-07	6.15e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—NOS3—breast cancer	8.82e-07	6.14e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTEN—breast cancer	8.69e-07	6.05e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—breast cancer	8.62e-07	6e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CA—breast cancer	8.62e-07	6e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFB1—breast cancer	8.6e-07	5.99e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGFR—breast cancer	8.43e-07	5.87e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—breast cancer	8.34e-07	5.81e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CAV1—breast cancer	8.15e-07	5.68e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CB—breast cancer	8.14e-07	5.66e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—breast cancer	8.06e-07	5.61e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—breast cancer	7.98e-07	5.55e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—breast cancer	7.97e-07	5.55e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	7.79e-07	5.42e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CA—breast cancer	7.72e-07	5.38e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTEN—breast cancer	7.71e-07	5.37e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—breast cancer	7.63e-07	5.31e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CG—breast cancer	7.43e-07	5.17e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CA—breast cancer	7.32e-07	5.1e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—breast cancer	7.04e-07	4.9e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTEN—breast cancer	7.03e-07	4.9e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—breast cancer	6.77e-07	4.72e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CD—breast cancer	6.53e-07	4.55e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—breast cancer	6.48e-07	4.51e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALB—breast cancer	6.45e-07	4.49e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—breast cancer	6.31e-07	4.39e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NOS3—breast cancer	6.17e-07	4.29e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CA—breast cancer	6.13e-07	4.27e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—breast cancer	5.98e-07	4.16e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CB—breast cancer	5.69e-07	3.96e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—breast cancer	5.64e-07	3.93e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CA—breast cancer	5.44e-07	3.79e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—breast cancer	5.01e-07	3.49e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CA—breast cancer	4.96e-07	3.45e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTEN—breast cancer	4.92e-07	3.42e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—breast cancer	4.45e-07	3.09e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—breast cancer	4.05e-07	2.82e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CA—breast cancer	3.47e-07	2.42e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—breast cancer	2.83e-07	1.97e-06	CbGpPWpGaD
